AstraZeneca has initiated a Phase III trial to study the effects of the triple-combination inhaled therapy BREZTRI AEROSPHERE® (budesonide/glycopyrronium/formoterol fumarate, or BGF) on severe cardiopulmonary outcomes in people with chronic obstructive pulmonary disease (COPD). This trial aims to investigate the potential impact of BGF on cardiopulmonary events, including death, in COPD patients with elevated cardiopulmonary risk, regardless of their exacerbation history.
Additionally, the ATHLOS trial, which compares AstraZeneca’s triple therapy BGF with ICS/LABA budesonide/formoterol fumarate (BFF) or placebo, has dosed its first participants. This trial focuses on assessing cardiopulmonary parameters such as hyperinflation and exercise endurance time, which are linked to health status and survival.
COPD affects a significant global population, leading to increased risks of pulmonary and cardiac events, including severe COPD exacerbations and cardiac issues. The THARROS trial, led by Fernando Martinez, MD, MS, and David Berg, MD, MPH, aims to provide critical evidence on the efficacy of triple-combination therapy in reducing severe cardiopulmonary events and improving treatment outcomes in COPD patients.
Sharon Barr, Executive Vice President of BioPharmaceuticals R&D at AstraZeneca, emphasizes the importance of addressing COPD as a leading cause of death and highlights the potential of triple therapy to mitigate cardiopulmonary risks.
BGF is currently approved for COPD treatment in various countries globally, including the US, EU, China, and Japan.
The article also includes important safety information regarding BREZTRI AEROSPHERE® and advises caution in its use based on specific patient conditions and potential drug interactions.
